ABSTRACT
This paper is part of a growing body of research work looking at the synthesis of an optimal adsorbent for the capture and containment of aqueous radioiodine from nuclear fuel reprocessing waste. 32 metalated commercial ion exchange resins were subjected to a two-tier screening assessment for their capabilities in the uptake of iodide from aqueous solutions. The first stage determined that there was appreciable iodide capacity across the adsorbent range (12-220 mg·g-1). Candidates with loading capacities above 40 mg·g-1 were progressed to the second stage of testing, which was a fractional factorial experimental approach. The different adsorbents were treated as discrete variables and concentrations of iodide, co-contaminants and protons (pH) as continuous variables. This gave rise to a range of extreme conditions, which were representative of the industrial challenges of radioiodine abatement. Results were fitted to linear regression models, both for the whole dataset (R 2 = 59%) and for individual materials (R 2 = 18-82%). The overall model determined that iodide concentration, nitrate concentration, pH and interactions between these factors had significant influences on the uptake. From these results, the top six materials were selected for project progression, with others discounted due to either poor uptake or noticeable iodide salt precipitation behaviour. These candidates exhibited reasonable iodide uptake in most experimental conditions (average of >20 mg·g-1 hydrated mass), comparing favourably with literature values for metallated adsorbents. Ag-loaded Purolite S914 (thiourea functionality) was the overall best-performing material, although some salt precipitation was observed in basic conditions. Matrix effects not withstanding it is recommended that metalated thiourea, bispicolylamine, and aminomethylphosphonic acid functionalized silicas warrant further exploration.
ABSTRACT
The orexin system plays a major role in the integration of metabolic and circadian influences that drive wakefulness. This paper describes initial Phase I trials of a novel dual orexin receptor antagonist SB-649868 that has demonstrated preclinical potential for treatment of sleep disorders. The trial designs included a single ascending dose escalation study (dose range: 10-80 mg in the fed and fasted states) and a multiple repeat dose study (dose range: 5-30 mg in the fed state) enrolling a total of 103 male volunteer subjects. SB-649868 was well tolerated at all doses in this study population, with mechanism-related adverse events (e.g. somnolence and fatigue) observed in a majority of subjects after 60 and 80 mg single doses. Although total drug exposure was similar in the fed and fasted states, the rate, but not the extent, of absorption increased in the fed state, resulting in an increased C(max). The typical estimated half-life of SB-649868 was 3-6 h - comparable with currently used hypnotic agents. Repeated administration of SB-649868 dose-dependently increased exposure to simvastatin (10 mg), suggesting CYP3A4 inhibition ranging from very mild (5 mg) to strong (30 mg). Evening dosing resulted in significant dose-dependent improvement in latency to persistent sleep, total sleep time and wake after sleep onset as measured by polysomnography. Next-morning testing did not detect evidence of residual cognitive effects. Results of these trials support further investigation of SB-649868 and other dual orexin receptor antagonists as potentially effective and well-tolerated treatments for patients with sleep disorders.